FISONS SEES STRONG INTERNATIONAL GROWTH IN 1986
Fisons Plc <FISN.L> said strong
international growth had been the main feature of the group's
1986 progress, with the pharmaceutical division reporting a 50
pct increase in U.S. Sales during the period.
    The rise was due to a sustained marketing programme, a
larger sales force and the introduction of an aerosol form of
its Intal anti-asthma drug, which pushed U.S. Sales up 70 pct.
    The company was commenting on 1986 results which saw
pre-tax profits rising to 85.1 mln stg from 72.3 mln in 1985.
The result was in line with market forecasts, but its shares
nevertheless eased in a falling market to 634p at 0857 GMT from
643p.
    Fisons said the potential for future growth of Intral, as
well as its Opticrom and Nasalcrom products, was clearly
indicated by a strong 1986 performance.
    The scientific equipment business had raised the proportion
of high technology products it manufactures and also raised its
ability to generate higher margins. The horticulture operations
had demonstrated outstanding marketing ability. Underlying cash
flow from all three operations had been positive despite a full
programme of capital investment.
    Action to protect the group against foreign currency
movements resulted in a small net gain to profits.
 REUTER
